PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

CapsoVision, Inc.

PosiFunda Ratios Only on PositoAI

PositoAI's own ratios from CapsoVision, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.

Cash quality

Profit Cash Ratio

—

Data incomplete

Self-Funding Ratio

—

Data incomplete

Cash Locked Ratio

—

Data incomplete

Growth quality

Steadiness Ratio

—

Data incomplete

Growth Efficiency Ratio

—

Data incomplete

Asset Productivity Ratio

—

Data incomplete

Balance-sheet strength

Debt Due Cover Ratio

-55.8×

Operating cash was negative last year, while some debt falls due within a year.

Lower than 75% of Healthcare companies in United States.

Cash Cushion Ratio

+3%

Cash, after subtracting all debt, equals 3% of its market value (net cash).

Lower than 63% of Healthcare companies in United States.

Tangible Assets Ratio

—

Data incomplete

Tangible Net Worth Ratio

—

Data incomplete

Shareholders

Shareholder Slice Ratio

—

Data incomplete

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (12)

CapsoVision, Inc. made a loss over the last year. CapsoVision, Inc. owes $0.29 for every $1 it owns. CapsoVision, Inc. made a loss in each of the last two years.

Compared with Healthcare companies in United States · latest annual results Dec 2025.

P/E ratio

Loss

CapsoVision, Inc. made a loss over the last year, so its P/E ratio is not meaningful.

P/B ratio

28.25

The share price is 28.25 times CapsoVision, Inc.'s book value per share, higher than 96% of Healthcare companies in United States.

Market cap

$372 M

The total market value of all of CapsoVision, Inc.'s shares at today's price (share price × number of shares), larger than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.

Net worth (book value)

$13 M

What CapsoVision, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).

Book value per share

$0.25

Net worth divided by the number of shares. The share price of $6.99 is 28.3 times this, which is the P/B above.

Return on equity (ROE)

-335.1%

CapsoVision, Inc. lost 335.1% of its shareholders' money over the last year, lower than 90% of Healthcare companies in United States.

Owes vs Owns

0.29×

CapsoVision, Inc. owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.

Dividend yield

None

CapsoVision, Inc. does not currently pay a dividend.

Revenue growth

+15%

Revenue rose 15% in the year to Dec 2025.

Profit growth

Loss

CapsoVision, Inc. made a loss in each of the last two years.

Profit margin

-186.8%

CapsoVision, Inc. lost $187 for every $100 of revenue.

Cash vs debt

Net cash

CapsoVision, Inc. held $9 M more cash than debt (net cash) at Dec 2025.

Questions

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For CapsoVision, Inc.: $372 M ÷ $13 M (30 Jun 2026) = 28.3.

What is CapsoVision, Inc.'s return on equity?

CapsoVision, Inc. lost 335.1% of its shareholders' money over the last year, lower than 90% of Healthcare companies in United States.

How much does CapsoVision, Inc. owe compared with what it owns?

CapsoVision, Inc. owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.

Does CapsoVision, Inc. pay a dividend?

No. CapsoVision, Inc. does not currently pay a dividend.

Is CapsoVision, Inc.'s revenue growing?

Revenue rose 15% in the year to Dec 2025.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.